Supplemental Digital Content

SDC, Table S1. Available Data and Completion Rate for the (A) MDASI-MM and (B) EQ-5D-3L by Treatment

1. MDASI-MM

| Assessment Time Point, n (%) | EPd ITT Population | Pd ITT Population |
| --- | --- | --- |
| Randomizeda | Expectedb | Randomizeda | Expectedb |
| Screening | 53/60 (88.3) | 53/53 (100.0) | 47/57 (82.5) | 47/48 (97.9) |
| Cycle 2 | 44/60 (73.3) | 44/51 (86.3) | 40/57 (70.2) | 40/44 (90.9) |
| Cycle 3 | 44/60 (73.3) | 44/46 (95.7) | 35/57 (61.4) | 35/37 (94.6) |
| Cycle 4 | 38/60 (63.3) | 38/44 (86.4) | 32/57 (56.1) | 32/34 (94.1) |
| Cycle 5 | 38/60 (63.3) | 38/41 (92.7) | 26/57 (45.6) | 26/29 (89.7) |
| Cycle 6 | 36/60 (60.0) | 36/39 (92.3) | 20/57 (35.1) | 20/25 (80.0) |
| Cycle 7 | 34/60 (56.7) | 34/38 (89.5) | 17/57 (29.8) | 17/19 (89.5) |
| Cycle 8 | 33/60 (55.0) | 33/35 (94.3) | 15/57 (26.3) | 15/16 (93.8) |
| Cycle 9 | 27/60 (45.0) | 27/34 (79.4) | 14/57 (24.6) | 14/15 (93.3) |
| Cycle 10 | 25/60 (41.7) | 25/28 (89.3) | 12/57 (21.1) | 12/14 (85.7) |
| Cycle 11 | 25/60 (41.7) | 25/26 (96.2) | 10/57 (17.5) | 10/12 (83.3) |
| Cycle 12 | 25/60 (41.7) | 25/26 (96.2) | 10/57 (17.5) | 10/11 (90.9) |
| Cycle 13 | 24/60 (40.0) | 24/25 (96.0) | 10/57 (17.5) | 10/10 (100.0) |
| Cycle 14 | 17/60 (28.3) | 17/23 (73.9) | 7/57 (12.3) | 7/10 (70.0) |
| Cycle 15 | 17/60 (28.3) | 17/18 (94.4) | 6/57 (10.5) | 6/7 (85.7) |
| Cycle 16 | 18/60 (30.0) | 18/18 (100.0) | 4/57 (7.0) | 4/6 (66.7) |
| Cycle 17 | 15/60 (25.0) | 15/18 (83.3) | 5/57 (8.8) | 5/5 (100.0) |
| Cycle 18 | 14/60 (23.3) | 14/16 (87.5) | 5/57 (8.8) | 5/5 (100.0) |
| Cycle 19 | 14/60 (23.3) | 14/15 (93.3) | 4/57 (7.0) | 4/5 (80.0) |
| Cycle 20 | 14/60 (23.3) | 14/15 (93.3) | 3/57 (5.3) | 3/5 (60.0) |
| Cycle 21 | 14/60 (23.3) | 14/15 (93.3) | 3/57 (5.3) | 3/4 (75.0) |
| Cycle 22 | 14/60 (23.3) | 14/15 (93.3) | 4/57 (7.0) | 4/4 (100.0) |
| Cycle 23 | 14/60 (23.3) | 14/14 (100.0) | 4/57 (7.0) | 4/4 (100.0) |
| Cycle 24 | 13/60 (21.7) | 13/14 (92.9) | 4/57 (7.0 | 4/4 (100.0) |
| Cycle 25 | 12/60 (20.0) | 12/14 (85.70) | 4/57 (7.0) | 4/4 (100.0) |
| Cycle 26 | 11/60 (18.3) | 11/11 (100.0) | 3/57 (5.3) | 3/4 (75.0) |
| Cycle 27 | 11/60 (18.3) | 11/11 (100.0) | 2/57 (3.5) | 2/4 (50.0) |
| Cycle 28 | 10/60 (16.7) | 10/11 (90.9) | 3/57 (5.3) | 3/4 (75.0) |
| Cycle 29 | 8/60 (13.3) | 8/10 (80.0) | 2/57 (3.5) | 2/3 (66.7) |
| End of treatment | 40/60 (66.7) | 40/47 (85.1) | 29/57 (50.9) | 29/43 (67.4) |
| Survival FU 1 | 16/60 (26.7) | 16/41 (39.0) | 10/57 (17.5) | 10/37 (27.0) |
| Survival FU 2 | 12/60 (20.0) | 12/34 (35.3) | 9/57 (15.8) | 9/30 (30.0) |
| Survival FU 3 | 10/60 (16.7) | 10/28 (35.7) | 10/57 (17.5) | 10/25 (40.0) |
| Survival FU 4 | 9/60 (15.0) | 9/28 (32.1) | 9/57 (15.8 | 9/21 (42.9) |
| Survival FU 5 | 12/60 (20.0) | 12/26 (46.2) | 6/57 (10.5) | 6/19 (31.6) |
| Survival FU 6 | 10/60 (16.7) | 10/22 (45.5) | 7/57 (12.3) | 7/17 (41.2) |

Data only shown for treatment cycles with ≥10 expected patients or FU visits with ≥10 completions.

a Number at risk includes number randomized. Completion rate consists of the proportion of completed questionnaires over the number at risk at each time point.

b Number at risk includes number expected to have a PRO assessment (ie, alive and not dropped out of study). Completion rate consists of the proportion of completed questionnaires over the number at risk at each time point.

EPd, elotuzumab + pomalidomide + dexamethasone; EQ-5D-3L, 3-level EQ-5D; FU, follow-up; ITT, intent-to-treat; MDASI-MM, MD Anderson Symptom Inventory for Multiple Myeloma; Pd, pomalidomide + dexamethasone; PRO, patient-reported outcome.

1. EQ-5D-3L

| Assessment Time Point, n (%) | EPd ITT Population | Pd ITT Population |
| --- | --- | --- |
| Randomizeda | Expectedb | Randomizeda | Expectedb |
| Screening | 60/60 (100.0) | 60/60 (100.0) | 56/57 (98.2) | 56/57 (98.2) |
| Cycle 2 | 50/60 (83.3) | 50/57 (87.7) | 50/57 (87.7) | 50/53 (94.3) |
| Cycle 3 | 50/60 (83.3) | 50/52 (96.2) | 43/57 (75.4) | 43/46 (93.5) |
| Cycle 4 | 43/60 (71.7) | 43/50 (86.0) | 40/57 (70.2) | 40/42 (95.2) |
| Cycle 5 | 42/60 (70.0) | 42/46 (91.3) | 34/57 (59.6) | 34/37 (91.9) |
| Cycle 6 | 40/60 (66.7) | 40/43 (93.0) | 27/57 (47.4) | 27/33 (81.8) |
| Cycle 7 | 37/60 (61.7) | 37/42 (88.1) | 22/57 (38.6) | 22/26 (84.6) |
| Cycle 8 | 36/60 (60.0) | 36/38 (94.7) | 18/57 (31.6) | 18/21 (85.7) |
| Cycle 9 | 30/60 (50.0) | 30/37 (81.1) | 17/57 (29.8) | 17/19 (89.5) |
| Cycle 10 | 28/60 (46.7) | 28/31 (90.3) | 15/57 (26.3) | 15/17 (88.2) |
| Cycle 11 | 28/60 (46.7) | 28/29 (96.6) | 12/57 (21.1) | 12/15 (80.0) |
| Cycle 12 | 28/60 (46.7) | 28/29 (96.6) | 11/57 (19.3) | 11/13 (84.6) |
| Cycle 13 | 27/60 (45.0) | 27/28 (96.4) | 11/57 (19.3) | 11/11 (100.0) |
| Cycle 14 | 20/60 (33.3) | 20/26 (76.9) | 8/57 (14.0) | 8/11 (72.7) |
| Cycle 15 | 20/60 (33.3) | 20/21 (95.2) | 7/57 (12.3) | 7/8 (87.5) |
| Cycle 16 | 21/60 (35.0) | 21/21 (100.0) | 5/57 (8.8) | 5/7 (71.4) |
| Cycle 17 | 18/60 (30.0) | 18/21 (85.7) | 6/57 (10.5) | 6/6 (100.0) |
| Cycle 18 | 18/60 (30.0) | 18/19 (94.7) | 6/57 (10.5) | 6/6 (100.0) |
| Cycle 19 | 17/60 (28.3) | 17/18 (94.4) | 5/57 (8.8) | 5/6 (83.3) |
| Cycle 20 | 16/60 (26.7) | 16/18 (88.9) | 4/57 (7.0) | 4/6 (66.7) |
| Cycle 21 | 16/60 (26.7) | 16/17 (94.1) | 4/57 (7.0) | 4/5 (80.0) |
| Cycle 22 | 16/60 (26.7) | 16/17 (94.1) | 5/57 (8.8) | 5/5 (100.0) |
| Cycle 23 | 16/60 (26.7) | 16/16 (100.0) | 5/57 (8.8) | 5/5 (100.0) |
| Cycle 24 | 15/60 (25.0) | 15/16 (93.8) | 5/57 (8.8) | 5/5 (100.0) |
| Cycle 25 | 14/60 (23.3) | 14/16 (87.5) | 5/57 (8.8) | 5/5 (100.0) |
| Cycle 26 | 13/60 (21.7) | 13/13 (100.0) | 4/57 (7.0) | 4/5 (80.0) |
| Cycle 27 | 12/60 (20.0) | 12/13 (92.3) | 3/57 (5.3) | 3/5 (60.0) |
| Cycle 28 | 11/60 (18.3) | 11/13 (84.6) | 4/57 (7.0) | 4/5 (80.0) |
| Cycle 29 | 9/60 (15.0) | 9/11 (81.8) | 3/57 (5.3) | 3/4 (75.0) |
| End of treatment | 44/60 (73.3) | 44/54 (81.5) | 34/57 (59.6) | 34/49 (69.4) |
| Survival FU 1 | 12/60 (20.0) | 12/47 (25.5) | 9/57 (15.8) | 9/41 (22.0) |
| Survival FU 2 | 10/60 (16.7) | 10/38 (26.3) | 9/57 (15.8) | 9/34 (26.5) |

Data only shown for treatment cycles with ≥10 expected patients or FU visits with ≥10 completions.

a Number at risk includes number randomized. Completion rate consists of the proportion of completed questionnaires over the number at risk at each time point.

b Number at risk includes number expected to have a PRO assessment (ie, alive and not dropped out of study). Completion rate consists of the proportion of completed questionnaires over the number at risk at each time point.

EPd, elotuzumab + pomalidomide + dexamethasone; EQ-5D-3L, 3-level EQ-5D; FU, follow-up; ITT, intent-to-treat; Pd, pomalidomide + dexamethasone; PRO, patient-reported outcome